文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

头盔式无创通气治疗ICU外低氧性肺炎:COVID-19疫情期间的观察性研究

Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak.
PubMed 文献 · Crit Care · 2021-02-24
一句话结论在ICU外,头盔CPAP治疗COVID-19肺炎所致的低氧性呼吸衰竭是可行的,可持续数天,标准氧疗失败后多数完整治疗患者无需升级至插管。

这项观察性研究纳入306例因COVID-19肺炎导致标准氧疗(非再呼吸面罩)失败的患者,在ICU外使用自由流动头盔CPAP系统治疗。42%的患者为DNI(有护理限制,不插管)。头盔CPAP在完整治疗患者中成功率为69%,在DNI患者中为28%(P < 0.001)。使用头盔CPAP后,PaO2/FiO2比值从约100 mmHg升至200 mmHg(P < 0.001),呼吸频率从28次/分降至24次/分(P < 0.001)。C反应蛋白、氧疗面罩失败时间、年龄、CPAP期间的PaO2/FiO2、合并症数量与CPAP失败独立相关。头盔CPAP维持6[3-9]天,前两日几乎连续使用。完整治疗患者在病房内插管前无死亡。

要点

  • 在ICU外,头盔CPAP治疗COVID-19肺炎低氧性呼吸衰竭是可行的,可持续6[3-9]天。
  • 完整治疗患者中头盔CPAP成功率为69%,DNI患者为28%(P < 0.001)。
  • 头盔CPAP使PaO2/FiO2从约100 mmHg升至200 mmHg(P < 0.001),呼吸频率从28[22-32]次/分降至24[20-29]次/分(P < 0.001)。
  • C反应蛋白、氧疗面罩失败时间、年龄、CPAP期间PaO2/FiO2、合并症数量与CPAP失败独立相关。
  • 完整治疗患者在病房内插管前无死亡。

适用人群与场景

  • 因COVID-19肺炎导致标准氧疗(非再呼吸面罩)失败的患者。
  • 包括完整治疗患者和有护理限制(DNI)的患者,均在ICU外治疗。

诊断标准与关键阈值

  • 标准氧疗失败定义为使用非再呼吸面罩后仍存在低氧血症。
  • CPAP失败定义为插管或死亡的复合结局。

处置流程与药物剂量

  • 使用自由流动头盔CPAP系统进行治疗。
  • 在开始CPAP前、开始时及之后每天记录患者数据。
  • 头盔CPAP维持6[3-9]天,前两日几乎连续使用。

研究设计与关键结果

  • 观察性研究,共纳入306例患者,42%为DNI。
  • 头盔CPAP治疗成功率:完整治疗患者69%,DNI患者28%(P < 0.001)。
  • PaO2/FiO2比值从约100 mmHg升至200 mmHg(P < 0.001)。
  • 呼吸频率从28[22-32]次/分降至24[20-29]次/分(P < 0.001)。
  • C反应蛋白、氧疗面罩失败时间、年龄、CPAP期间PaO2/FiO2、合并症数量与CPAP失败独立相关。
  • 头盔CPAP维持6[3-9]天,前两日几乎连续使用。
  • 完整治疗患者在病房内插管前无死亡。

证据类型、等级与局限

  • 证据类型:观察性研究。
  • 试验注册号:NCT04424992。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ICU外,头盔CPAP可作为COVID-19肺炎标准氧疗失败后的治疗选择,可持续数天。
  • 对于完整治疗患者,头盔CPAP可在多数情况下避免升级至插管。
  • 对于DNI患者,头盔CPAP可作为挽救治疗以改善生存。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Respiratory failure due to COVID-19 pneumonia is associated with high mortality and may overwhelm health care systems, due to the surge of patients requiring advanced respiratory support. Shortage of intensive care unit (ICU) beds required many patients to be treated outside the ICU despite severe gas exchange impairment. Helmet is an effective interface to provide continuous positive airway pressure (CPAP) noninvasively. We report data about the usefulness of helmet CPAP during pandemic, either as treatment, a bridge to intubation or a rescue therapy for patients with care limitations (DNI).

METHODS: In this observational study we collected data regarding patients failing standard oxygen therapy (i.e., non-rebreathing mask) due to COVID-19 pneumonia treated with a free flow helmet CPAP system. Patients' data were recorded before, at initiation of CPAP treatment and once a day, thereafter. CPAP failure was defined as a composite outcome of intubation or death.

RESULTS: A total of 306 patients were included; 42% were deemed as DNI. Helmet CPAP treatment was successful in 69% of the full treatment and 28% of the DNI patients (P < 0.001). With helmet CPAP, PaO2/FiO2 ratio doubled from about 100 to 200 mmHg (P < 0.001); respiratory rate decreased from 28 [22-32] to 24 [20-29] breaths per minute, P < 0.001). C-reactive protein, time to oxygen mask failure, age, PaO2/FiO2 during CPAP, number of comorbidities were independently associated with CPAP failure. Helmet CPAP was maintained for 6 [3-9] days, almost continuously during the first two days. None of the full treatment patients died before intubation in the wards.

CONCLUSIONS: Helmet CPAP treatment is feasible for several days outside the ICU, despite persistent impairment in gas exchange. It was used, without escalating to intubation, in the majority of full treatment patients after standard oxygen therapy failed. DNI patients could benefit from helmet CPAP as rescue therapy to improve survival.

TRIAL REGISTRATION: NCT04424992.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Coppadoro A, Benini A, Fruscio R, et al. Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. Crit Care. 2021. PMID: 33627169. doi:10.1186/s13054-021-03502-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。